00868nam a22002533i 450099100247924970753620030630091630.0030925s1971 it |||||||||||||||||ita b1229441x-39ule_instARCHE-034198ExLBiblioteca InterfacoltàitaA.t.i. Arché s.c.r.l. Pandora Sicilia s.r.l.843.91Livi, François387919Camus /di Francois LiviFirenze :La nuova Italia,1971139 p. ;17 cmIl castoro ;49Camus, Albert.b1229441x02-04-1408-10-03991002479249707536LE002 Coll. 27.4912002000104366le002-E0.00-no 00000.i1268864208-10-03Camus163821UNISALENTOle00208-10-03ma -itait 0104840nam 22009253u 450 991014639730332120231129014806.01-280-30974-197866103097401-84692-556-8(CKB)1000000000463450(EBL)362703(OCoLC)476194143(SSID)ssj0000258330(PQKBManifestationID)12112418(PQKBTitleCode)TC0000258330(PQKBWorkID)10257141(PQKB)10109792(EXLCZ)99100000000046345020130418d2005|||| u|| |engur|n|---|||||txtccrTherapeutic Strategies in Lymphoid Malignancies[electronic resource] An Immunotherapeutic ApproachOxford Atlas Medical Publishing Ltd20051 online resource (238 p.)Therapeutic StrategiesDescription based upon print version of record.1-904392-52-0 Contents; Contributors; 1. The history of immunotherapy for lymphoid malignancies; 2. Immunological markers of lymphoid malignancy; 3. Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenetic and haematological parameters; 4. CD20: B-cell antigen and therapeutic target; 5. Rituximab and chemotherapy for non-Hodgkin's lymphomas: improved response and survival; 6. Rituximab and chemotherapy in elderly patients with lymphomas; 7. Maintenance therapy with rituximab; 8. Interferon-alpha in lymphoid malignancies9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (ZevalinTM) for B-cell Hodgkin's lymphoma; 11. Radioimmunotherapy combinations with other therapies for non-Hodgkin's lymphoma; 12. 131I-Tositumomab therapy for the treatment ofl ow-grade non-Hodgkin's lymphoma; 13. CD52 as a target for immunotherapy; 14. Relapsed and refractory CLL: a clinical challenge15. Optimising the use of alemtuzumab in CLL: new therapeutic end points, disease stratification and therapy earlier in the disease course16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders; 17. The role of alemtuzumab in allogeneic stem cell transplantation; 18. Alemtuzumab in T-cell malignancies; 19. Epratuzumab: A new humanised monoclonal antibody to CD22; 20. Education and management of patients undergoing immunotherapy and radioimmunotherapy; 21. Antibody therapy for chronic lymphocytic leukemia; IndexTargeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drugTherapeutic StrategiesCancerLymphaticsLymphomaLymphomaImmunotherapyLymphoproliferative DisordersNeoplasms by Histologic TypeImmunomodulationLymphatic DiseasesBiological TherapyImmunoproliferative DisordersNeoplasmsImmune System DiseasesDiseaseTherapeuticsHemic and Lymphatic DiseasesDiagnostic Techniques and ProceduresCancer.Lymphatics.Lymphoma.Lymphoma.Immunotherapy.Lymphoproliferative Disorders.Neoplasms by Histologic Type.Immunomodulation.Lymphatic Diseases.Biological Therapy.Immunoproliferative Disorders.Neoplasms.Immune System Diseases.Disease.Therapeutics.Hemic and Lymphatic Diseases.Diagnostic Techniques and Procedures.616.994420637Hillmen P1001216Witzig TE1001217AU-PeELAU-PeELAU-PeELBOOK9910146397303321Therapeutic Strategies in Lymphoid Malignancies2298040UNINA